Home
World Journal of Biology Pharmacy and Health Sciences
ISSN Approved | International, Peer reviewed, Referred, Open access Journal

Main navigation

  • Home
    • Journal Information
    • Abstracting and Indexing
    • Editorial Board Members
    • Reviewer Panel
    • Journal Policies
    • WJBPHS CrossMark Policy
    • Publication Ethics
    • Current Issue
    • Issue in Progress
    • Past Issues
    • Instructions for Authors
    • Article processing fee
    • Track Manuscript Status
    • Get Publication Certificate
    • Become a Reviewer panel member
    • Join as Editorial Board Member
  • Contact us
  • Downloads

ISSN Approved Journal | | IMPACT FACTOR 8.16 | | eISSN: 2582-5542 | |  Free Crossref DOI 

Fast Publication within 2 days | | Low Article Processing Charges | | Peer Reviewed and Referred Journal

Research and review articles are invited for publication in September 2026 (Volume 27, Issue 3) Submit Paper

A case report on montelukast and fexofenadine induced depression and nightmares

Breadcrumb

  • Home
  • A case report on montelukast and fexofenadine induced depression and nightmares

CHRISTEENA MARY VIJI 1, *, THOMAS JACOB ABRAHAM 2 , HARIKRISHNAN S 3

1 Pharm D Intern Nazareth College of Pharmacy, Othera, Kerala, India.
2 Associate Professor, Department of General Medicine, Believers church medical college hospital, Thiruvalla, Kerala, India.
3 Clinical Pharmacist Believers Church Medical College Hospital, Kerala, India.
 

Case Report

World Journal of Biology Pharmacy and Health Sciences, 2025, 21(02), 111–113

Article DOI: 10.30574/wjbphs.2025.21.2.0114

DOI url: https://doi.org/10.30574/wjbphs.2025.21.2.0114

Received on 19 December 2024; revised on 31 January 2025; accepted on 02 February 2025

Depression and nightmares are caused by Montelukast. Montelukast is a selective leukotriene receptor antagonist (LRTA) and US-FDA issued a black box warning in 2020. In this case report, a 14 year old female was prescribed a combination of Tab. Montelukast and Tab. Fexofenadine for the treatment of bronchial asthma exacerbations. After this, she started experiencing multiple episodes of depression and nightmares. The patient was asked to avoid Montelukast after which the patient's condition improved and she was started on MDI Formoterol fumarate and Budesonide powder for inhalation and Tab. Desloratadine for further management. After stopping the drug, her condition improved. This case report underlines the importance of monitoring for rare but serious side effects of leukotriene receptor antagonist and highlights the need for further research into their mechanisms and risk factors. 

Montelukast; Depression; Nightmare; Bronchial asthma; Fexofenadine

https://wjbphs.com/sites/default/files/fulltext_pdf/WJBPHS-2025-0114.pdf

Preview Article PDF

VIJI MARY CHRISTEENA, ABRAHAM JACOB THOMAS and S HARIKRISHNAN. A case report on montelukast and fexofenadine induced depression and nightmares. World Journal of Biology Pharmacy and Health Sciences, 2025, 21(02), 111–113. Article DOI: https://doi.org/10.30574/wjbphs.2025.21.2.0114

 

Get Certificates

Get Publication Certificate

Download LoA

Check Corssref DOI details

Issue details

Issue Cover Page

Editorial Board

Table of content


Copyright © Author(s). All rights reserved. This article is published under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as appropriate credit is given to the original author(s) and source, a link to the license is provided, and any changes made are indicated.


Copyright © 2026 World Journal of Biology Pharmacy and Health Sciences (WJBPHS) - All rights reserved

Developed & Designed by VS Infosolution